PPFIA1 Antibody

What is PPFIA1 and what cellular functions does it regulate?

PPFIA1 (PTPRF Interacting Protein Alpha 1) encodes liprin-α1, a member of the leukocyte common antigen-related protein tyrosine phosphatase (LAR-RPTPs)-interacting protein family. The protein functions as a scaffold for recruiting and anchoring LAR phosphatases and plays critical roles in:

• Regulation of focal adhesion disassembly

• Cell migration and invasion processes

• Localization of receptor-like tyrosine phosphatases type 2A at specific plasma membrane sites

• Cytoskeletal organization, particularly vimentin intermediate filament network

• Modulation of integrin signaling pathways

Liprin-α1 is a multivalent protein that can form complex structures and homodimerize via its N-terminal coiled-coil regions. It's ubiquitously expressed across tissues and has been shown to interact with tumor suppressor ING4 to regulate cell migration .

What applications are commonly used with PPFIA1 antibodies?

PPFIA1 antibodies are validated for multiple applications in research settings:

• Western Blotting (WB): Typically used at dilutions between 1:300-1:5000, depending on the specific antibody

• Immunohistochemistry (IHC-P and IHC-F): Optimal working dilutions range from 1:100-1:500

• Immunofluorescence (IF): Used at dilutions of 1:50-1:200 for both IHC-P and IHC-F samples

• Immunocytochemistry (ICC): Effective for studying subcellular localization

• ELISA: Applicable at dilutions of 1:500-1:1000

When selecting an antibody, verify the specific applications it has been validated for, as not all antibodies perform equally across all techniques. The PPFIA1 protein has a predicted molecular weight of approximately 136 kDa, which should be used as a reference point for band identification in Western blots .

How should I validate a PPFIA1 antibody before experimental use?

A systematic validation approach for PPFIA1 antibodies should include:

• Western blot validation:

  • Test in cell lines with known PPFIA1 expression (e.g., Jurkat, RT-4, U-251 MG cells)

  • Verify the correct molecular weight (predicted: 136 kDa)

  • Include positive controls (cell lines with high endogenous expression) and negative controls (knockdown cells using shRNA constructs)

• Specificity testing:

  • Compare results using at least two different antibodies targeting different epitopes of PPFIA1

  • One validated approach uses a PPFIA1 antibody (1:500; A10388, ABclonal, UK) that has shown a single band of the predicted size (135 kDa) in BT474 human breast cancer cell lysate

• Immunohistochemistry optimization:

  • Optimize antigen retrieval conditions

  • Determine optimal antibody dilution through titration (typically starting at 1:100)

  • Include appropriate tissue controls

  • For IHC, cytoplasmic staining for PPFIA1 in invasive tumor cells can be evaluated using the modified histochemical score (H-score)

• Knockdown validation:

  • Generate PPFIA1 knockdown cells using validated shRNA constructs (e.g., TRCN0000002969, TRCN0000342514, TRCN0000380944)

  • Compare antibody reactivity between wildtype and knockdown samples

How does liprin-α1 (PPFIA1) contribute to endocrine resistance in breast cancer?

PPFIA1 has been identified as a potential marker for predicting poor response to endocrine therapy in luminal breast cancer through several mechanisms:

• Clinical correlation data:

  • Patients with high PPFIA1 expression show significantly poorer outcomes when treated with endocrine therapy alone

  • High PPFIA1 mRNA was significantly correlated with shorter recurrence, distant metastasis, and reduced survival (P < 0.05) in patients receiving endocrine treatment

  • Multivariate Cox regression analysis confirmed PPFIA1 protein expression as an independent prognostic marker for clinical outcome in patients receiving endocrine treatment (HR 2.5, 95% CI 1.3–5.0, P = 0.006)

• Experimental methodology:

  • To study PPFIA1's role in endocrine resistance, researchers compared PPFIA1 mRNA expression between patients who received endocrine treatment and relapsed (unresponsive) with those who did not relapse (responsive)

  • Results showed significantly higher PPFIA1 expression in unresponsive patients (P < 0.0001)

  • Protein expression analysis using immunohistochemistry confirmed these findings with a cutoff of >15 H-score for high PPFIA1 expression

• Molecular associations:

  • PPFIA1 expression positively correlates with CCND1 (a cell cycle regulator), which is known to be associated with impaired response to tamoxifen

  • PPFIA1 shows negative association with the tumor suppressor CD82, which inhibits cell migration and invasion via regulation of integrin-mediated signaling

To investigate PPFIA1's role in endocrine resistance, researchers should consider both transcriptomic (mRNA) and proteomic (protein) expression levels, as both have demonstrated clinical value in predicting therapy response.

What is the relationship between PPFIA1 expression and MAPK signaling pathways?

PPFIA1 has been identified as a contributor to oncogenic MAPK signaling through several key interactions:

• Drug sensitivity profiles:

  • Large-scale drug screening revealed that MEK/ERK inhibitors show differential responses between high PPFIA1-expressing and PPFIA1-silenced cells

  • In KRAS-mutated MDA-MB-231 cells, PPFIA1 knockdown led to increased resistance to trametinib (MEK inhibitor)

  • In head and neck squamous cell carcinoma (HNSCC) cells with low RAS activity, context-dependent responses to MEK/ERK inhibitors were observed

• Biochemical interactions:

  • PPFIA1 depletion consistently leads to increased phosphorylated ERK1/2 (p-ERK1/2) levels across multiple cell lines, regardless of KRAS mutational status

  • This suggests a role for liprin-α1 in regulating MAPK oncogenic signaling

  • PPFIA1 knockdown caused more pronounced redistribution of RAS proteins to the cell membrane

• Methodological approaches to study this interaction:

  • Drug sensitivity and resistance testing (DSRT) with oncology compound libraries

  • Western blot analysis of phosphorylated ERK levels in control vs. PPFIA1-depleted cells

  • Membrane fractionation studies to examine RAS protein localization

  • Stable transduction of cells with validated shRNA constructs targeting PPFIA1

This evidence suggests that PPFIA1 status may be an important factor in predicting drug responses to MAPK pathway inhibitors in a context-dependent manner, and should be considered when designing targeted therapy approaches.

How does liprin-α1 regulate vimentin intermediate filament networks in cancer cells?

Liprin-α1 has been identified as a novel regulator of tumor cell intermediate filaments with differential oncogenic properties:

• Structural interaction with cytoskeleton:

  • Liprin-α1 localizes to different adhesion and cytoskeletal structures, particularly affecting the vimentin intermediate filament network

  • This interaction significantly alters invasion and growth properties of cancer cells

• Cell-type specific effects:

  • In non-invasive cells: Liprin-α1 promotes expansive growth behavior with limited invasive capacity

  • In invasive cells: Liprin-α1 has significant impact on mesenchymal cancer cell invasion in three-dimensional collagen models

• Experimental approaches to study this interaction:

  • Three-dimensional collagen matrix models to assess invasive properties

  • Immunofluorescence microscopy to visualize co-localization with vimentin networks

  • Live-cell imaging to track dynamic changes in intermediate filament organization

  • Proximity ligation assays to detect direct protein interactions

• Mechanistic insights:

  • Liprin-α1 appears to function as a scaffold that recruits regulatory proteins to modulate vimentin organization

  • The effect on vimentin may explain the differential behavior in proliferating versus motile cancer cells

These findings identify liprin-α1 as an important regulator of tumor cell cytoskeletal architecture with context-dependent effects on cancer cell phenotypes.

What technical considerations are important when using PPFIA1 antibodies for studying sub-cellular localization?

When investigating the sub-cellular localization of PPFIA1 using immunofluorescence or related techniques, researchers should consider:

• Fixation and permeabilization protocols:

  • PFA/Triton X-100 fixation has been successfully used for visualizing PPFIA1 in U-2 OS cells at 4 μg/mL antibody concentration

  • Avoid overfixation which may mask epitopes, particularly when studying membrane-associated fractions

• Antibody selection criteria:

  • Choose antibodies validated specifically for immunofluorescence applications

  • Consider epitope location - antibodies targeting different regions (N-terminal vs. C-terminal) may yield different localization patterns

  • Available validated antibodies include those targeting:

    • N-terminal region (aa 1-250)

    • Middle region (aa 450-650)

    • Other regions such as aa 141-190/1202

• Controls and validation:

  • Include PPFIA1 knockdown cells as negative controls

  • Consider co-staining with markers for relevant cellular structures:

    • Focal adhesion markers (paxillin, vinculin)

    • Cell membrane markers

    • Cytoskeletal elements (particularly vimentin)

• Expected localization patterns:

  • Primary subcellular locations: Cytoplasm and cell membrane

  • In cancer cells, liprin-α1 localizes to adhesive and invasive structures in the cell periphery

  • May show different patterns in invasive versus non-invasive cells

• Image acquisition parameters:

  • Use appropriate confocal settings to properly visualize membrane versus cytoplasmic localization

  • Consider live-cell imaging approaches for studying dynamic localization changes

How can PPFIA1 expression be quantified in patient samples for potential use as a predictive biomarker?

For robust quantification of PPFIA1 expression in patient samples, consider these methodological approaches:

• Immunohistochemistry (IHC) quantification:

  • Modified histochemical score (H-score) has been validated for evaluating cytoplasmic staining for PPFIA1 in invasive tumor cells

  • A cutoff of >15 H-score has been used to define high PPFIA1 protein expression in luminal breast tumors

  • TMA cores should only be assessed if invasive tumor burden is >15%

  • Careful consideration of antibody dilution (1:100 has been validated with antibody A10388, ABclonal, UK)

• mRNA expression analysis:

  • Transcriptomic analysis shows high correlation with protein levels

  • High PPFIA1 mRNA expression was observed in 1129/1398 (81%) of cases in the METABRIC cohort

  • Dichotomization of PPFIA1 mRNA/protein expression can be determined using X-Tile (X-Tile Bioinformatics Software, Yale University)

• Statistical analysis approaches:

  • Chi-square test for evaluating association between PPFIA1 expression and clinicopathological parameters

  • Pearson's correlation coefficient for correlation between continuous normalized data

  • Kaplan-Meier survival curves to investigate association with clinical outcome

  • Cox regression analysis to evaluate independent prognostic significance

  • Apply Benjamini–Hochberg procedure for multiple test correction

• ELISA-based quantification:

  • Commercial ELISA kits are available with detection range of 0.313-20 ng/mL and sensitivity of <0.188 ng/mL

  • Suitable for quantifying PPFIA1 in serum, plasma, and tissue homogenates

• Validation across cohorts:

  • Results should be validated across independent patient cohorts

  • The METABRIC, KM-Plotter and bc-GenExMiner v4.3 datasets have been used successfully for validation

What are the best approaches for generating and validating PPFIA1 knockdown models?

For effective PPFIA1 knockdown models, consider these validated approaches:

• shRNA-based stable knockdowns:

  • Validated shRNA constructs from TRC1 and TRC2 libraries:

    • TRCN0000002969 (shPPFIA_1)

    • TRCN0000342514 (shPPFIA1_2)

    • TRCN0000380944 (shPPFIA1_3)

  • Use scramble shRNA (SHC002) as control

  • Most effective construct reported: TRCN0000002969 for knockdown efficiency

• Lentiviral expression systems:

  • ORF for PPFIA1 (clone ID 4794300) can be cloned from donor pENTR221 vector into lentiviral destination expression vector (e.g., pLenti6/V5 DEST)

  • Gateway cloning system has been successfully used for this purpose

• Validation approaches:

  • Western blot analysis using validated antibodies

  • qRT-PCR to confirm mRNA reduction

  • Ideally use at least two different shRNA constructs to control for off-target effects

  • Confirm phenotypic relevance through functional assays (migration, invasion)

• Experimental considerations:

  • Cell-type specific effects may occur - test in multiple relevant cell lines

  • For breast cancer studies, MDA-MB-231 and BT-474 cell lines have been validated

  • For HNSCC studies, UT-SCC-42A, UT-SCC-24A, and UT-SCC-95 have been used

How can I analyze the effect of PPFIA1 on distant metastasis in breast cancer models?

To investigate PPFIA1's role in distant metastasis, researchers should consider these methodological approaches:

• Clinical correlation analysis:

  • High PPFIA1 mRNA expression is significantly associated with distant metastasis to specific sites:

    • Liver

    • Brain

    • Bone

    • Lung (P < 0.05)

  • This site-specific pattern suggests organ-specific mechanisms worth exploring

• In vitro models:

  • 3D collagen matrix invasion assays to assess invasive capacity

  • Transwell migration and invasion assays

  • Compare PPFIA1 wildtype and knockdown cells

  • PPFIA1 has been shown to enhance cell spreading and migration in various models

• Molecular pathway analysis:

  • Examine correlations with:

    • Integrin signaling components (PPFIA1 is an essential regulator of integrin signaling)

    • CD82 (negative correlation suggests mechanism of action)

    • PPFIBPI (liprin-β1) which cooperates with PPFIA1 in regulating tumor cell migration

• Animal models:

  • Xenograft models comparing wildtype and PPFIA1-depleted cells

  • Tail vein injection models to study organ-specific tropism

  • Assessment of circulating tumor cells

• Technical considerations:

  • Assess both PPFIA1 mRNA and protein expression

  • Context-dependent effects may occur in different breast cancer subtypes

  • The relationship between PPFIA1 and endocrine resistance suggests hormone-dependent mechanisms

What are the challenges in developing therapeutic strategies targeting PPFIA1?

Developing therapeutic strategies against PPFIA1 presents several research challenges:

• Target complexity:

  • PPFIA1 functions primarily as a scaffold protein without enzymatic activity

  • Interacts with multiple binding partners in different cellular contexts

  • Located in the 11q13 amplicon alongside other potential oncogenes like CCND1

  • Affects multiple downstream pathways including MAPK signaling

• Context-dependent roles:

  • Contradictory roles reported in different cancer types:

    • In head and neck cancer cells, depletion enhances migration

    • In breast cancer cells, depletion decreases migration and ECM degradation

    • Differential effects in invasive versus non-invasive cells

  • This context-dependency complicates therapeutic strategy design

• Biomarker development challenges:

  • Need for standardized quantification methods:

    • H-score cutoffs for IHC

    • Standardized mRNA expression thresholds

  • Validation across multiple cohorts is essential

  • Integration with other biomarkers (e.g., CCND1, CD82) may be necessary

• Potential approaches:

  • Disruption of protein-protein interactions rather than direct inhibition

  • Combined targeting with endocrine therapy in breast cancer

  • Context-specific targeting based on cancer type and cellular phenotype

  • Exploration of synthetic lethality approaches with MEK/ERK inhibitors

• Experimental models:

  • Patient-derived xenografts to capture heterogeneity

  • 3D organoid models to better recapitulate tumor microenvironment

  • Combination therapy testing platforms

What are the optimal storage and handling conditions for PPFIA1 antibodies?

For maintaining optimal antibody performance:

• Storage conditions:

  • Store according to manufacturer's instructions, typically 4°C for short-term or -20°C for long-term storage

  • Avoid repeated freeze-thaw cycles which can degrade antibody quality

  • Some antibodies are stored in 50% glycerol buffers to minimize freeze-thaw damage

• Buffer composition:

  • Typical storage buffers include:

    • 0.01M TBS (pH 7.4) with 1% BSA

    • 0.02% Proclin300 as preservative

    • 50% Glycerol for stability

• Shelf-life considerations:

  • Typical shelf-life of 6 months if stored properly

  • Performance should be tested if used near expiration date

  • Loss rate of activity should be less than 5% within the expiration date under appropriate conditions

• Working dilution preparation:

  • Prepare working dilutions fresh on the day of experiment

  • Maintain cold chain during dilution preparation

  • Use appropriate diluents as recommended by manufacturer

• Quality control:

  • Always include positive controls in experiments

  • Consider testing new lots against previous lots for consistency

  • Operation procedures and lab conditions should be strictly controlled to minimize performance fluctuations

How can I troubleshoot non-specific binding when using PPFIA1 antibodies in Western blotting?

When encountering non-specific binding issues:

• Antibody validation:

  • Confirm antibody specificity using:

    • Positive controls (cell lines with known PPFIA1 expression)

    • Negative controls (PPFIA1 knockdown cells)

  • Verify the predicted molecular weight (136 kDa)

  • Test multiple antibodies targeting different epitopes

• Blocking optimization:

  • Try different blocking agents (BSA vs. non-fat milk)

  • Increase blocking time and/or concentration

  • Add 0.1-0.5% Tween-20 to reduce non-specific binding

• Antibody dilution:

  • Titrate antibody concentration (typical range: 1:300-1:5000)

  • Increase antibody incubation time at lower concentrations

  • Consider overnight incubation at 4°C with more dilute antibody

• Washing protocols:

  • Increase washing duration and number of washes

  • Add higher concentration of detergent to wash buffers

  • Consider using phosphate buffers instead of Tris for some antibodies

• Sample preparation:

  • Ensure complete protein denaturation

  • Test different lysis buffers

  • Add protease inhibitors to prevent degradation

  • Freshly prepare samples when possible

• Detection system:

  • Try alternative secondary antibodies

  • Reduce exposure time when using chemiluminescence

  • Consider fluorescent-based detection for better quantification

What controls should be included when assessing PPFIA1 expression in clinical samples?

For robust analysis of clinical samples:

• Positive tissue controls:

  • Include tissues with known high PPFIA1 expression

  • Breast cancer tissues with 11q13 amplification

  • Validated cell lines embedded in paraffin blocks:

    • BT474 human breast cancer cells have shown consistent PPFIA1 expression

• Negative controls:

  • Antibody omission controls

  • Isotype controls to assess non-specific binding

  • Normal adjacent tissue (when appropriate)

  • Tissues with confirmed low PPFIA1 expression

• Technical validation:

  • Include TMA cores with >15% invasive tumor burden

  • For prognostic studies, include samples with known clinical outcomes

  • Process all samples using identical protocols for staining and evaluation

• Scoring controls:

  • Use the modified histochemical score (H-score) for cytoplasmic staining evaluation

  • Have at least two independent observers score samples

  • Include reference images representing different staining intensities

• Multi-level validation:

  • When possible, validate protein expression findings with mRNA data

  • Consider digital pathology tools for standardized quantification

  • Statistical controls for multiple comparisons (e.g., Benjamini–Hochberg procedure)